StockWatch
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultJul 30, 2026, 04:07 PM

Myriad Genetics Q2 Revenue Down 11% to $190.7M; Revises FY26 Guidance

AI Summary

Myriad Genetics reported second-quarter 2026 revenue of $190.7 million, an 11% decrease year-over-year, resulting in a net loss of $43.2 million. The company revised its full-year 2026 revenue guidance lower to $770-$790 million, citing challenges in Prenatal Health and increased payer friction. Despite the financial downturn, Myriad launched new products like Prolaris + AI and FirstGene, expanded its Precise MRD offerings, and initiated strategic efficiency programs to drive future growth and profitability.

Key Highlights

  • Q2 2026 revenue decreased 11% year-over-year to $190.7 million.
  • Reported Q2 2026 net loss of $43.2 million, or $(0.46) per share.
  • Adjusted Q2 2026 net loss was $(23.4) million, or $(0.25) per share.
  • Cancer Care Continuum revenue was $114.1 million, down 11% YoY, with volume up 8%.
  • Prenatal Health revenue was $39.8 million, down 16% YoY, with volume down 9%.
  • Mental Health revenue was $36.8 million, down 3% YoY, with volume up 4%.
  • Revised full-year 2026 revenue guidance to $770-$790 million.
  • Launched Prolaris + AI for prostate cancer and FirstGene Multiple Prenatal Screen.